Final-LogoTw

Developing Next-Generation Activated Protein C for Human Therapeutic Use

ZZ Biotech, LLC - Developing Innovative Biologic Treatments

ZZ Biotech LLC is a clinical stage company developing innovative biologic treatments for ischemic stroke, amyotrophic lateral sclerosis (ALS), other neurological diseases, and wound healing applications including the treatment of diabetic foot ulcers. The US Food and Drug Administration (FDA) has designated the investigation of the company’s experimental drug 3K3A-APC for the treatment of acute ischemic stroke as a Fast Track development program.

zzbiotechH

THE COMPANY
ZZ Biotech LLC is a clinical stage company developing innovative biologic treatments for ischemic stroke, amyotrophic lateral sclerosis (ALS), other neurological diseases, and diabetic foot ulcers. ZZ Biotech was formed to focus on the development of 3K3A-APC.

stroke-programH

STROKE PROGRAM
ZZ Biotech has completed RHAPSODY, a Phase 2 clinical study. The FDA has designated the investigation of the company’s experimental drug 3K3A-APC for the treatment of acute ischemic stroke as a Fast Track development program.

brain

ALS PROGRAM
The beneficial mechanisms of APC in treating ALS have been explored, and APC mutants have shown efficacy in rodent models of ALS. A Phase 2 biomarker study in ALS patients is planned for 2020.

foot-ulcer-treatment

WOUND HEALING PROGRAM
APC and 3K3A-APC have shown efficacy in several in vitro and in vivo wound healing studies. APC has also been studied in multiple human clinical wound healing studies, including a foot ulcer study.